Core Insights - Bigbank achieved record high loans to customers of 2.7 billion euros, increasing by 127 million euros (+5%) quarter-on-quarter and 511 million euros (+23%) year-on-year, driven by business and home loan products [1][11] - The total deposit portfolio grew to 2.9 billion euros, with a quarterly increase of 152 million euros (+6%) and an annual increase of 486 million euros (+20%) [2][11] - The net profit for 2025 reached 37.9 million euros, a growth of 5.6 million euros compared to 2024, reflecting a 17% increase [3][11] Loan Portfolio - The business loan portfolio increased by 90 million euros (+10%) to 1.0 billion euros, while the home loan portfolio rose by 47 million euros (+6%) to 820 million euros [1] - The consumer loan portfolio decreased by 24 million euros (-3%) to 854 million euros, primarily due to the sale of a 20 million euro portfolio from the Swedish branch [1] Deposit Portfolio - The term deposit portfolio grew by 86 million euros (+7%) to 1.4 billion euros, and the savings deposit portfolio increased by 54 million euros, also reaching 1.4 billion euros [2] - Current accounts increased by 11 million euros to 20 million euros, with new offerings for corporate customers in Estonia [2] Financial Performance - Interest income for Q4 was 46.9 million euros, an increase of 3.5 million euros (+8%) year-on-year, while interest expense decreased by 0.8 million euros (-4%) [4] - Net interest income rose by 4.3 million euros (+18%) to 27.5 million euros for Q4, and full-year net interest income increased by 3.8 million euros (+4%) to 106.2 million euros [4] Credit Quality - The net expected credit loss allowances decreased by 1.0 million euros year-on-year to 3.6 million euros in Q4, with a 50% reduction for the full year [5] - The volume of stage 3 loans was 118 million euros, accounting for 4.3% of the total loan portfolio, showing a decrease in risk [5] Team and Operational Growth - The number of staff increased by 26 during Q4 and by 79 during the year (+14%), reaching a total of 639 employees [6] - Salary expenses rose to 10.0 million euros in Q4, exceeding the previous year's figure by 1.7 million euros (+20%) [6] Investment Property - The investment property portfolio increased to 84.7 million euros, reflecting a growth of 2.4 million euros during Q4 and 18.3 million euros during the year [7] Equity and Capital Position - Bigbank's equity reached an all-time high of 299.4 million euros, with a return on equity (ROE) of 13.3%, up by 0.8 percentage points from 2024 [8] - The group successfully completed a public Tier 2 bond issue and direct placements of Additional Tier 1 (AT1) instruments, enhancing stability [14] Everyday Banking Services - Bigbank expanded its everyday banking capabilities, launching current account services for retail and corporate customers and introducing a new mobile app [12][13] - By the end of 2025, Bigbank served over 19,000 current account customers across the Baltics, indicating strong customer growth [13]

Core Insights - ForFarmers achieved a record year in 2025 with a total feed volume of 10.6 million tonnes and a net profit increase of 52.5% [1] - The company experienced significant growth due to favorable market conditions, including low raw material prices and high selling prices for milk, eggs, and meat [1] - Strategic initiatives, such as the joint venture with KPS in Poland and the integration of Van Triest, have strengthened ForFarmers' market position [1] Financial Performance - Total volume increased by 18.0% compared to 2024, with a like-for-like growth of 1.0% when excluding acquisitions [6] - Gross profit rose by 17.9% to €611.2 million, contributing to a 44.7% increase in underlying EBITDA to €145.9 million [6] - Underlying net profit attributable to shareholders increased by 52.5% to €61.9 million, with strong net cash flow from operating activities of €148.3 million [6] Market Position and Strategy - ForFarmers is a leading player in Europe with production operations in the Netherlands, Germany, Poland, and the UK, and exports to various countries [5] - The company is focused on strengthening the Dutch poultry value chain through investments and acquisitions [6] - The recent joint venture with KPS Food Group is expected to significantly enhance ForFarmers' position in the growing Polish poultry market [6] Sustainability and Future Outlook - The company is making good progress on CO2 reduction and increasing the share of co-products [6] - Despite volatile market conditions and geopolitical uncertainties, the company remains optimistic about growth opportunities in the European agricultural sector [1]

Company Overview - argenx is a global immunology company focused on improving the lives of individuals suffering from severe autoimmune diseases [3] - The company is known for developing and commercializing the first approved neonatal Fc receptor (FcRn) blocker, with ongoing evaluations of its potential in various serious autoimmune diseases [3] Upcoming Events - argenx will host a conference call and audio webcast on February 26, 2026, at 2:30 PM CET (8:30 AM ET) to discuss its full year 2025 financial results and provide a fourth quarter business update [1] - The live call can be accessed via the Investors section of the argenx website, with a replay available for approximately one year following the presentation [2] Contact Information - Media inquiries can be directed to Ben Petok at bpetok@argenx.com [4] - Investor relations can be contacted through Alexandra Roy at aroy@argenx.com [4]

Core Insights - Nestlé reported a positive performance in 2025, achieving a real internal growth (RIG) of 0.8% and organic growth of 3.5%, despite a challenging external environment [2][4][29] - The company is accelerating its strategic focus on four core businesses: Coffee, Petcare, Nutrition, and Food & Snacks, which together account for approximately 70% of sales [3][8][16] - Nestlé's financial performance included a free cash flow of CHF 9.2 billion and a proposed dividend increase to CHF 3.10 per share, reflecting a commitment to shareholder returns [4][43][44] Financial Performance - Total reported sales decreased by 2.0% to CHF 89.5 billion, with a gross profit margin of 45.6%, down 110 basis points from the previous year [4][33][41] - Underlying trading operating profit (UTOP) was CHF 14.4 billion, a decrease of 8.4%, with a UTOP margin of 16.1% [4][36] - Net profit fell by 17.0% to CHF 9.0 billion, with basic earnings per share decreasing to CHF 3.51 [4][41] Strategic Focus - The company is prioritizing RIG-led growth and expanding its high-potential growth platforms to represent 30% of sales, supported by an additional CHF 0.6 billion investment in 2026 [3][19][28] - Nestlé is simplifying its organizational structure to enhance local accountability and drive efficiencies, with a target of CHF 1 billion in annual savings by 2027 [21][22][26] - The integration of Nutrition and Nestlé Health Science into a single business aims to strengthen category leadership and drive synergies [8][17] Market Trends - Organic growth in developed markets was 2.3%, while emerging markets saw a higher growth rate of 5.4%, indicating a robust performance across various regions [32][51] - E-commerce sales grew by 13.5%, reaching 20.5% of total Group sales, highlighting the importance of digital channels in driving growth [32][82] - The company experienced significant improvements in market share trends, with billionaire brands showing positive growth for the first time in over a decade [30][31] Cost Management - Nestlé's Fuel for Growth program exceeded its savings target, achieving CHF 1.1 billion in savings, which supported margin delivery despite inflationary pressures [35][36] - The company is focused on optimizing working capital and capital expenditures, with a disciplined approach to cash generation and capital allocation [23][24] Future Guidance - For 2026, Nestlé expects organic growth to be in the range of 3% to 4%, with RIG anticipated to accelerate, despite potential impacts from the infant formula recall [10][14][28] - The UTOP margin is expected to improve compared to 2025, with free cash flow projected to exceed CHF 9 billion [14][28]

Core Insights - Kinepolis reported solid results for 2025 despite a challenging environment, with a revenue decline limited to -2.3% and a visitor drop of -5.8% compared to the previous year [1] - The adjusted EBITDAL for 2025 was € 128.2 million, reflecting a decrease of -3.4%, while the adjusted net result remained nearly unchanged from 2024 [1] - Excluding negative currency effects, revenue decline was only -0.3%, amounting to € 576.6 million, with adjusted EBITDAL at € 130.2 million, down -1.9% [1] - The start of 2026 is promising due to successful films and strategic acquisitions, positioning Kinepolis well for future growth [1] Financial Performance - Revenue decline of -2.3% in 2025, with a visitor decrease of -5.8% [1] - Adjusted EBITDAL of € 128.2 million, down -3.4% [1] - Adjusted net result remained stable compared to 2024 [1] - Revenue excluding currency effects declined by -0.3% to € 576.6 million [1] - Adjusted EBITDAL excluding currency effects was € 130.2 million, down -1.9% [1] Strategic Developments - Successful refinancing with a new € 160 million revolving credit facility and a public bond issuance of € 150 million [6] - Commitment to premiumization with the addition of new IMAX screens, ScreenX, and Laser ULTRA auditoriums [6] - Renovation of several cinemas, including locations in France and Canada [6] - Acquisition of US-based Emagine Entertainment to enhance market presence [6] - Transition to sustainable laser projection with 75% of screens equipped [6]

19 February 2026, 7:00 am, Antwerp, Belgium: VGP NV (‘VGP’ or ‘the Group’), a European provider of high-quality logistics and semi-industrial real estate, today announces the results for the full year ended 31 of December 2025: A pre-tax profit of € 338 million, an increase of € 19 million or 6% versus FY’24. Net asset value growth of 8.3%, up to € 2.6 billion. EPRA NTA is up 9%. EBITDA growth of 28% to € 454.7 million, surpassed only by 2021, which benefited from exceptionally strong logistics demand durin ...

PRESS RELEASE | Arcadis Fourth Quarter and Full Year Results 2025 Mixed results, repositioning for next growth phase FOURTH QUARTER Net revenues of €887 million, organic growth of -2.9%Operating EBITA margin of 10.8% (Q4‘24: 12.6%)Extensive Property & Investment (within Places) project portfolio review led to revenue adjustments Record free cash flow performance of €344 million (Q4‘24: €183 million) FULL YEAR Net revenues of €3.8 billion, organic growth -0.5% with areas of strength offset by PlacesBacklog o ...

Core Viewpoint - BioVersys AG announced promising Phase 2a clinical trial results for AlpE, a novel antibacterial product aimed at treating pulmonary tuberculosis (TB), published in the New England Journal of Medicine, highlighting its potential to address multidrug-resistant (MDR) TB [1][7]. Company Overview - BioVersys AG is a clinical stage biopharmaceutical company focused on developing novel antibacterial products for serious infections caused by MDR bacteria, with its most advanced programs targeting nosocomial infections and tuberculosis [14]. Clinical Trial Details - The Phase 2a bEto-TB clinical trial, conducted in South Africa, demonstrated AlpE's early bactericidal activity in patients with pulmonary TB, suggesting it could replace isoniazid in current treatment regimens or be added to future therapies [3][5]. - The trial was completed in April 2024 and involved a collaboration with TASK, GSK, and BioVersys [3]. Drug Mechanism and Collaboration - Alpibectir (AlpE) operates through a novel mechanism that enhances the efficacy of the existing antibiotic ethionamide, identified through a collaboration with GSK and academic institutions [2][5]. - The development of AlpE has been supported by various European Union grants and public-private partnerships, including the EU Innovative Medicines Initiative [4]. Industry Context - Tuberculosis remains a leading cause of death from infectious diseases globally, with increasing drug resistance complicating treatment efforts. In 2024, an estimated 10.7 million people developed TB, with approximately 1.23 million fatalities [9][10]. - The burden of TB is concentrated in 30 high-burden countries, with India, Indonesia, and the Philippines among the top contributors to global TB cases [11].

Core Viewpoint - The company ICG plc has announced a share buyback program of up to 15,280,825 ordinary shares, representing approximately 5.26% of its issued share capital, to facilitate the issuance of non-voting shares to Amundi as part of a strategic partnership [2][3][4]. Share Buyback Program - The share buyback aims to reduce the issued ordinary share capital and will be executed in tranches, with repurchased shares held as treasury shares before eventual cancellation [4][6]. - The total consideration for the repurchased ordinary shares will not exceed £316 million, and the program will commence on 26 February 2026 and expire on 30 June 2027, unless the 2025 Authority expires without renewal [7][8]. - The buyback will be conducted on the London Stock Exchange and will adhere to market regulations, with a maximum price set at 105% of the average market quotations for the five business days preceding the purchase [9][10]. Non-Voting Shares - The non-voting shares will have the same nominal value and economic rights as ordinary shares but will not carry voting rights. They will convert into ordinary shares upon a valid transfer under specific conditions [5][3]. - Amundi will reimburse ICG for reasonable costs associated with the share buyback, and the subscription price for the non-voting shares will match the price paid for the repurchased ordinary shares [3][4]. Appointment of Non-Executive Director - Vincent Mortier has been appointed as a Non-Executive Director, effective from 31 March 2026, as part of the strategic partnership with Amundi. He will also serve on the Nominations and Governance Committee [11][12]. - Mortier brings extensive experience from his roles at Amundi and Societe Generale, which is expected to enhance the expertise of ICG's Board [12][13].

Louvain-la-Neuve, Belgium – 19 February 2026 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology with a preeminent position in nuclear medicine, and Shreeji (Shreeji Imaging and Diagnostic Centre Pvt. Ltd.), a leading Indian manufacturer and distributor of fluorodeoxyglucose (FDG) and positron emission tomography (PET) radiopharmaceuticals, have signed a multi-site agreement for the delivery and installation of four mid-energy Cyclone® KIUBE 300 cyclotrons. The ...